Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2026

Conditions

Hormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer

Interventions

DRUG

Palbociclib

3 weeks on, 1 week off

All Listed Sponsors

lead

Helwan University

OTHER

NCT06338644 - Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. | Biotech Hunter | Biotech Hunter